Genentech
A Member of the Roche Group



TECENTRIQ® NOW HAS 5 APPROVALS IN LUNG CANCER

A new option in PD-L1–high 1L metastatic NSCLC

TECENTRIQ Lung Cancer Indications[1]*	
NEW APPROVAL **Metastatic Non-Small Cell Lung Cancer**	TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1–stained ≥50% of tumor cells [TC ≥50%] or PD-L1–stained tumor-infiltrating immune cells [IC] covering ≥10% of the tumor area [IC ≥10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
	TECENTRIQ, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated for the first-line treatment of adult patients with metastatic nonsquamous, non-small cell lung cancer (nsqNSCLC) with no EGFR or ALK genomic tumor aberrations.
	TECENTRIQ, in combination with paclitaxel protein-bound and carboplatin, is indicated for the first-line treatment of patients with metastatic nsqNSCLC with no EGFR or ALK genomic tumor aberrations.
	TECENTRIQ is indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.
Extensive-Stage Small Cell Lung Cancer	TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

*Please refer to accompanying Prescribing Information for a complete list of TECENTRIQ indications.

Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.

TECENTRIQ®
atezolizumab
840 mg / 1200 mg
INJECTION FOR IV USE

Patient Assistance Information

Genentech Oncology Access Solutions offers a range of access and reimbursement support to help patients begin treatment as soon as possible. We can help your patients by providing:

- Benefits investigations (BIs)
- Prior authorization (PA) resources
- Information about authorized specialty pharmacies (SPs) and specialty distributors
- Sample billing and coding information
- Resources for denials and appeals
- Patient assistance options

Codes for Your Reference

Type	Code	Description
TECENTRIQ NDC[1]	**50242-918-01 (on packaging) 50242-0918-01 (used for billing)**	840 mg/14 mL single-dose vial
	50242-917-01 (on packaging) 50242-0917-01 (used for billing)	1200 mg/20 mL single-dose vial
TECENTRIQ HCPCS[2]	**J9022**	Injection, atezolizumab, 10 mg
ICD-10-CM[3]	**C33**	Malignant neoplasm of trachea
	C34.00–C34.02	Malignant neoplasm of bronchus and lung, main bronchus
	C34.10–C34.12	Malignant neoplasm of upper lobe, bronchus or lung
	C34.20	Malignant neoplasm of middle lobe, bronchus or lung
	C34.30–C34.32	Malignant neoplasm of lower lobe, bronchus or lung
	C34.80–C34.82	Malignant neoplasm of overlapping sites, bronchus or lung
	C34.90–C34.92	Malignant neoplasm of unspecified part, bronchus or lung
CPT[4]	**96413**	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415	Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)
	96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (list separately in addition to code for primary procedure)

Abbreviations: CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification; NDC, National Drug Code.

The table above is provided for informational purposes only.

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

Distribution and Fulfillment Information

- TECENTRIQ is available through authorized specialty distributors and wholesalers
  - Visit **www.genentech-access.com/TECENTRIQ** for a list of distributors

If you have any distribution-related questions, please contact your representative or call the Genentech Customer Service Department at 1-800-551-2231, Monday through Friday, 6:00 AM to 5:00 PM Pacific Time.

Important Safety Information (cont'd)

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-mediated pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-mediated hepatitis.** Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.

Important Safety Information (cont'd)

- **Immune-mediated colitis.** Immune-mediated diarrhea or colitis have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-mediated endocrinopathies.** Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred
- **Other immune-mediated adverse reactions.** TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- **Infections.** Severe infections, including fatal cases, have occurred
- **Infusion-related reactions.** Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ alone were fatigue/asthenia (48%), decreased appetite (25%), nausea (24%), cough (22%), and dyspnea (22%).

The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with other antineoplastic drugs for NSCLC and SCLC were fatigue/asthenia (49%), nausea (38%), alopecia (35%), constipation (29%), diarrhea (28%), and decreased appetite (27%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

For more information, please contact your BioOncology Field Reimbursement Manager or Genentech Oncology Access Solutions for TECENTRIQ by calling 1-866-422-2377 or by visiting https://www.genentech-access.com/TECENTRIQ.

References: 1. TECENTRIQ [package insert]. South San Francisco, CA: Genentech, Inc; 2020. **2.** HCPCS J-Codes. https://hcpcs.codes/j-codes/. Accessed May 14, 2020. **3.** International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM): 2019 release of ICD-10-CM. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/icd/icd10cm.htm. Updated October 1, 1, 2019. Accessed May 14, 2020. **4.** CPT® code search. Find-a-code website. https://www.findacode.com/cpt/cpt-procedure-codes.html. Accessed May 14, 2020.

TECENTRIQ® | ACCESS SOLUTIONS®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

Genentech
A Member of the Roche Group